Preclinical acute ocular safety study of combined intravitreal carboplatin and etoposide phosphate for retinoblastoma

Brian G. Mohney, Victor M. Elner, Andrew B. Smith, J. William Harbour, Brian D. Smith, David C. Musch, Stephen J. Smith

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


BACKGROUND AND OBJECTIVE: To describe the ocular toxicity of intravitreal carboplatin and etoposide phosphate (VP16P) in Dutch-Belted rabbits. MATERIALS AND METHODS: Twenty-two adult male Dutch-Belted rabbits (Cohort 1) each received a single, bilateral intravitreal injection (0.05 mL). For Cohort 1, safety was assessed via electroretinograms (ERGs) and ocular examination. Of nine total groups in Cohort 1, the frst fve received the following single agents: Group 1: normal saline; Group 2: VP16P 75 μg; Group 3: VP16P 100 μg; Group 4: carboplatin 4 μg; and Group 5: carboplatin 8 μg. Groups 6 through 9 received the following combination of carboplatin/VP16P, respectively: Group 6: 8 μg/75 μg, Group 7: 8 μg/50 μg, Group 8: 4 μg/50 μg, and Group 9: 2 μg/25 μg. Cohort 2 consisted of 15 Dutch-Belted rabbits in seven groups (Groups 10 through 16), each receiving a single, bilateral intravitreal injection. For Cohort 2, safety was assessed via histopathology. RESULTS: Groups 2 through 8 demonstrated a statistically signifcant decrease (relative to Group 1) in at least one ERG waveform amplitude obtained 4 weeks postinjection (P <.05). Group 9 (carbo 2 μg/VP16P 25 μg) did not manifest ERG toxicity. Fundoscopic toxicity consisted of slight-to-moderate attenuation of vessels in rabbits receiving doses above carbo 4 μg/VP16P 50 μg. Histopathologic retinal toxicity (Cohort 2) was dose-dependent, ranging from full-thickness atrophy in rabbits receiving the highest dose to normal in rabbits receiving carbo 2 μg/VP16P 25 μg. CONCLUSIONS: Combined carboplatin and VP16P may be compatible for intravitreal injection therapy, and a single dose of 2 μg/25 μg appears to be safe in a rabbit model. These agents may be a safer alternative to intravitreal melphalan (Alkeran; GlaxoSmithKline, Brentford, United Kingdom) for the treatment of vitreous seeds in retinoblastoma.

Original languageEnglish (US)
Pages (from-to)151-159
Number of pages9
JournalOphthalmic Surgery Lasers and Imaging Retina
Issue number2
StatePublished - Feb 2017

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology


Dive into the research topics of 'Preclinical acute ocular safety study of combined intravitreal carboplatin and etoposide phosphate for retinoblastoma'. Together they form a unique fingerprint.

Cite this